Search Within

Joachim Yahalom

  1. "Erel Joffe"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (9)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Department of Medicine (31)
  2. Hematologic Malignancies, Division of (31)
  3. Radiation Oncology, Department of (31)
  4. Sloan Kettering Institute Postdocs (31)
  5. Survivorship Research (31)
  6. Center for Hematologic Malignancies (18)

More Groups

People
  1. Erel Joffe (31)
  2. Andrew Zelenetz (17)
  3. Ariela Noy (16)
  4. Brandon Imber (16)
  5. Maria Palomba (16)
  6. Paul Hamlin (16)

More People

Years
  1. 2024 (2)
  2. 2023 (7)
  3. 2022 (3)
  4. 2021 (7)
  5. 2020 (5)
  6. 2019 (7)
Publications
  1. Hematological Oncology (8)
  2. Blood (7)
  3. Blood Advances (4)
  4. International Journal of Radiation Oncology, Biology, Physics (3)
  5. Journal of Clinical Oncology (2)
  6. Leukemia and Lymphoma (2)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Wiley Blackwell (8)
  3. Elsevier Inc. (5)
  4. American Society of Clinical Oncology (2)
  5. Taylor & Francis Group (2)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (31)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
    Meeting Abstract

    Freret, M.; Imber, B.; Joffe, E.; Yahalom, J.; Hajj, C.
    Radiotherapy and Oncology (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Predictors of response to very low dose radiotherapy (4Gy) for indolent B-cell lymphomas: Is 4Gy also suitable for potentially curable patients?
    Meeting Abstract

    Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Chelius, M.; Hajj, C.; Wijetunga, N. A.; Yang, J. C.; Casey, D. L.; Shepherd, A. F.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?
    Journal Article

    Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save